Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Operating Expenses: 2016-2025

Historic Operating Expenses for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to $104.0 million.

  • Rhythm Pharmaceuticals' Operating Expenses rose 34.76% to $104.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.5 million, marking a year-over-year decrease of 4.63%. This contributed to the annual value of $395.6 million for FY2024, which is 51.13% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Operating Expenses of $104.0 million as of Q3 2025, which was up 10.82% from $93.8 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Operating Expenses peaked at $165.9 million during Q1 2024, and registered a low of $34.4 million during Q1 2021.
  • Its 3-year average for Operating Expenses is $85.0 million, with a median of $77.1 million in 2024.
  • Its Operating Expenses has fluctuated over the past 5 years, first spiked by 159.15% in 2024, then plummeted by 51.94% in 2025.
  • Rhythm Pharmaceuticals' Operating Expenses (Quarterly) stood at $52.8 million in 2021, then decreased by 3.62% to $50.9 million in 2022, then increased by 28.70% to $65.5 million in 2023, then rose by 26.85% to $83.1 million in 2024, then soared by 34.76% to $104.0 million in 2025.
  • Its last three reported values are $104.0 million in Q3 2025, $93.8 million for Q2 2025, and $79.7 million during Q1 2025.